Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized double blind placebo controlled trial to evaluate the
efficacy and safety of novel PAI-1 inhibitor (TM5614) for high-risk patients hospitalized
with severe COVID-19 at Northwestern Memorial Hospital. The patients will be randomized in a
1:1 ratio to receive standard of care plus TM5614 or standard of care plus placebo.